A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...

LifeVantage (LFVN) announced the completion of an international in vitro cell study that investigated the effects of its international ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Obesity is a growing concern worldwide, including in low- and middle-income countries (LMICs). Addressing this issue involves various strategies, including dietary and lifestyle changes, medical ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Viking Therapeutics stock plunged early Thursday on an earnings report that included mostly incremental updates for its ...

This is just a tiny glimpse of the data available to CivicScience clients. Discover more data. CivicScience has data on over ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

A small percentage of patients taking GLP-1 medications have experienced vision problems, but a direct causal link with the ...

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance. The approach is especially popular among telemedicine physicians, who ...

Direct-to-store model (delivering drugs directly to each retailer’s stores) of distributors are increasingly becoming more popular among retailers (represents 93% of sales in 2017, up from 74% in 2007 ...